LUBRIGONE | The first lubrication- and coating-free stoppers for Prefillable Syringes

Summary
With a global value of €4,663 million in 2017, Prefillable syringes (PFS) for administration of medical injections have seen an increased use in recent years, thanks to their advantages over the combined use of empty syringes and vials, such as their ease of use, accurate dosage (with less overfill), improved safety and reduced risk of contamination
However, PFS require lubrication (usually liquid or baked-on silicone) to ensure their functionality, and this lubrication (which is in direct contact with the medical dosage in the PFS throughout its entire shelf life) may affect the pharmaceutical compounds, reducing their efficacy and causing health and safety issues for patients.
To solve this problem, we developed LUBRIGONE, a new line of PFS stoppers combining a chemically inert Thermoplastic Elastomer (TPE) and unique sealing profile designs, which eliminates the need for lubrication and/or coating of the stopper and container. In this way, LUBRIGONE enables a completely clean injection system, protecting sensitive injectables from pollution, and protecting users against potential damage, while granting an optimal functionality (maintaining an acceptable break loose force and mean forces in PFS).
Our company, Injecto A/S was founded in 2014 with the goal to develop safe medical devices with primary focus on safe PFS syringes and their stoppers, to create safe and long-term stable drug injections. As a result, the LUBRIGONE project, will be a cornerstone for us, as it will enable us to exploit the market opportunity derived from its competitive advantages over current silicone-oil coated rubber stoppers, and the lack of feasible cost-effective alternatives, In this way, it will facilitate our growth and international expansion: our forecasts are to sell 21.4 million units in the first 4 years of commercialization, resulting in €10.7 million accumulated revenues by 2024, and increasing our staff by 250%
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/875949
Start date: 01-08-2019
End date: 30-11-2019
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

With a global value of €4,663 million in 2017, Prefillable syringes (PFS) for administration of medical injections have seen an increased use in recent years, thanks to their advantages over the combined use of empty syringes and vials, such as their ease of use, accurate dosage (with less overfill), improved safety and reduced risk of contamination
However, PFS require lubrication (usually liquid or baked-on silicone) to ensure their functionality, and this lubrication (which is in direct contact with the medical dosage in the PFS throughout its entire shelf life) may affect the pharmaceutical compounds, reducing their efficacy and causing health and safety issues for patients.
To solve this problem, we developed LUBRIGONE, a new line of PFS stoppers combining a chemically inert Thermoplastic Elastomer (TPE) and unique sealing profile designs, which eliminates the need for lubrication and/or coating of the stopper and container. In this way, LUBRIGONE enables a completely clean injection system, protecting sensitive injectables from pollution, and protecting users against potential damage, while granting an optimal functionality (maintaining an acceptable break loose force and mean forces in PFS).
Our company, Injecto A/S was founded in 2014 with the goal to develop safe medical devices with primary focus on safe PFS syringes and their stoppers, to create safe and long-term stable drug injections. As a result, the LUBRIGONE project, will be a cornerstone for us, as it will enable us to exploit the market opportunity derived from its competitive advantages over current silicone-oil coated rubber stoppers, and the lack of feasible cost-effective alternatives, In this way, it will facilitate our growth and international expansion: our forecasts are to sell 21.4 million units in the first 4 years of commercialization, resulting in €10.7 million accumulated revenues by 2024, and increasing our staff by 250%

Status

CLOSED

Call topic

EIC-SMEInst-2018-2020

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.0. INDUSTRIAL LEADERSHIP - Innovation In SMEs - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.0. Cross-cutting call topics
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1